Table 1.
Neurologic Context for EEG Studies in Patients With SARS-CoV-2.
| Neurologic Characteristics | n/Subset (%) |
|---|---|
| Past Seizure History | 1/37 (3%) |
| Past History of CNS Pathology | 8/37 (22%) |
| Past Psychiatric History | 16/37 (43%) |
| Altered Mental Status in the absence of sedation | 28/37 (76%) |
| Anosmia | 4/37 (11%) |
| New Focal Exam Finding | 3/37 (8%) |
| Known Acute CNS Injury | 9/37 (24%) |
| Empiric Anti-Epileptic Drug prior to EEG | 11/37 (30%) |
| Neuroimaging Performed | 35/37 (95%) |
| Computed Tomography (CT) | 35/37 (95%) |
| Magnetic Resonance Imaging (MRI) | 9/37 (24%) |
| MRIs performed with Gadolinium Contrast demonstrating Meningeal Enhancement | 0/7 (0%) |
| Neuroimaging Acutely Abnormal | 9/35 (26%) |
| Cerebrospinal Fluid (CSF) Testing | 4/37 (11%) |
| CSF Studies with Abnormal WBC or Protein | 3/4 (75%) |
| CSF Studies with Abnormal WBC (>5 cells/µL) | 2/4 (50%) |
| CSF Studies with Abnormal Protein | 1/4 (25%) |
| Reason for EEG | n/Subset (%) |
| Possible Seizure | 11/37 (30%) |
| Altered Mental Status | 24/37 (65%) |
| Cardiac Arrest | 2/37 (5%) |
| Sedation Context | n/Subset (%) |
| Recent sedation | 27/37 (73%) |
| Propofol | 19/27 (70%) |
| Dexmedetomidine | 13/27 (48%) |
| Midazolam or Lorazepam | 8/27 (30%) |
| Ketamine | 2/27 (7%) |
| Sedation targeted for ventilator dyssynchrony | 13/27 (48%) |
| Sedation decreased during EEG | 10/27 (37%) |